115 related articles for article (PubMed ID: 20559355)
1. US biotech firms line up for tax credits.
Ledford H
Nature; 2010 Jun; 465(7300):854-5. PubMed ID: 20559355
[No Abstract] [Full Text] [Related]
2. Biotechs get $1 billion windfall in R&D tax credits.
Thiel K
Nat Biotechnol; 2009 Dec; 27(12):1066. PubMed ID: 20010563
[No Abstract] [Full Text] [Related]
3. New tax credit program aims to revive ailing biotech research.
Clin Transl Sci; 2010 Oct; 3(5):200. PubMed ID: 21500422
[No Abstract] [Full Text] [Related]
4. Germany contemplates new biotech tax scheme.
Mitchell P
Nat Biotechnol; 2003 Jun; 21(6):587-8. PubMed ID: 12776130
[No Abstract] [Full Text] [Related]
5. US Supreme Court decision could compromise biotech patents.
Robertson D
Nat Biotechnol; 2001 May; 19(5):394. PubMed ID: 11328981
[No Abstract] [Full Text] [Related]
6. Surprise US election results may boost biotech.
Fox JL
Nat Biotechnol; 2002 Dec; 20(12):1176. PubMed ID: 12454655
[No Abstract] [Full Text] [Related]
7. A taxing dilemma.
Jacobs T
Nat Biotechnol; 2005 Oct; 23(10):1219. PubMed ID: 16211056
[No Abstract] [Full Text] [Related]
8. Ambitious French biotech plan faces EU hurdle.
Hodgson J
Nat Biotechnol; 2003 Feb; 21(2):113-4. PubMed ID: 12560821
[No Abstract] [Full Text] [Related]
9. Administrative costs for advance payment of health coverage tax credits: an initial analysis.
Dorn S
Issue Brief (Commonw Fund); 2007 Mar; 24():1-12. PubMed ID: 17419151
[TBL] [Abstract][Full Text] [Related]
10. A waiting game. Industry gives mixed reviews on R&D tax credits.
Rhea S
Mod Healthc; 2010 Sep; 40(37):12. PubMed ID: 21322314
[No Abstract] [Full Text] [Related]
11. Share slump brings biotech firms to government's door.
Check E
Nature; 2003 Jun; 423(6943):908. PubMed ID: 12827159
[No Abstract] [Full Text] [Related]
12. Pfizer-Pharmacia merger bodes ill for biotech?
Fletcher L
Nat Biotechnol; 2002 Sep; 20(9):857-8. PubMed ID: 12205489
[No Abstract] [Full Text] [Related]
13. Bioregios put Germany on the biodevelopment map.
Redhead CR
Nat Biotechnol; 1996 Dec; 14(13):1664-5. PubMed ID: 9634848
[No Abstract] [Full Text] [Related]
14. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
15. Public biotech 98: the numbers.
Lähteenmäki R; Michael A; Marshall A
Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
[No Abstract] [Full Text] [Related]
16. Biotech round the world: focus on Canada.
Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
[No Abstract] [Full Text] [Related]
17. [A scholar, fund holder, insurance and tax authority].
Elovainio L
Duodecim; 1995; 111(19):1897-901. PubMed ID: 9340294
[No Abstract] [Full Text] [Related]
18. Public biotech 2008--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2009 Aug; 27(8):710-21. PubMed ID: 19668175
[TBL] [Abstract][Full Text] [Related]
19. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
20. Market heats up for US biotech companies.
Gershon D
Nature; 1991 May; 351(6322):86. PubMed ID: 2030734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
